LON:DXRX

Diaceutics Final Earnings Results & Report

Diaceutics logo
GBX 182 -8.00 (-4.21%)
As of 11/20/2026 12:33 PM Eastern

Diaceutics reported Final earnings on May 26, 2026. The company reported EPS of GBX 11, while revenue was £38.44 million.

Earnings Announcement Details

Quarter
Final
Report Date
Time
Before Market Opens

Diaceutics EPS Results

Actual EPS
GBX 11
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Diaceutics Revenue Results

Actual Revenue
£38.44 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Diaceutics Final Earnings FAQ

Diaceutics (LON:DXRX) reported earnings of GBX 11 per share for Final. The report was announced on Tuesday, May 26, 2026.

Diaceutics reported revenue of £38.44 million for Final.

Diaceutics Earnings Headlines

Diaceutics (LON:DXRX) Stock: Insider Jordan Clark Sells 250,000 Shares
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Canaccord Genuity Group Reaffirms Buy Rating for Diaceutics (LON:DXRX)
Diaceutics (LON:DXRX) Stock Falls 1.4% - Here's Why
See More Diaceutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Diaceutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Diaceutics and other key companies, straight to your email.

About Diaceutics

At Diaceutics (LON:DXRX) we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

View Diaceutics Profile